Elevance Health Inc (ELV)vsLam Research Corp (LRCX)
ELV
Elevance Health Inc
$374.71
+1.53%
HEALTHCARE · Cap: $80.93B
LRCX
Lam Research Corp
$297.17
+7.75%
TECHNOLOGY · Cap: $320.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Elevance Health Inc generates 824% more annual revenue ($200.42B vs $21.68B). LRCX leads profitability with a 30.9% profit margin vs 2.6%. ELV appears more attractively valued with a PEG of 1.43. LRCX earns a higher WallStSmart Score of 74/100 (B).
ELV
Buy56
out of 100
Grade: C
LRCX
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.5%
Fair Value
$1011.48
Current Price
$374.71
$636.77 discount
Margin of Safety
+13.4%
Fair Value
$343.11
Current Price
$297.17
$45.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Generating 4.1B in free cash flow
Mega-cap, among the largest globally
Every $100 of equity generates 67 in profit
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 35.0%
Safe zone — low bankruptcy risk
Revenue surging 23.8% year-over-year
Areas to Watch
2.6% revenue growth
2.6% margin — thin
Weak financial health signals
Earnings declined 16.8%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 36.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ELV
The strongest argument for ELV centers on Market Cap, P/E Ratio, Price/Book. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bull Case : LRCX
The strongest argument for LRCX centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 30.9% and operating margin at 35.0%. Revenue growth of 23.8% demonstrates continued momentum.
Bear Case : ELV
The primary concerns for ELV are Revenue Growth, Profit Margin, Piotroski F-Score. Thin 2.6% margins leave little buffer for downturns.
Bear Case : LRCX
The primary concerns for LRCX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 48.5x leaves little room for execution misses.
Key Dynamics to Monitor
ELV profiles as a value stock while LRCX is a growth play — different risk/reward profiles.
LRCX carries more volatility with a beta of 1.79 — expect wider price swings.
LRCX is growing revenue faster at 23.8% — sustainability is the question.
ELV generates stronger free cash flow (4.1B), providing more financial flexibility.
Bottom Line
LRCX scores higher overall (74/100 vs 56/100), backed by strong 30.9% margins and 23.8% revenue growth. ELV offers better value entry with a 63.5% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Elevance Health Inc
HEALTHCARE · HEALTHCARE PLANS · USA
Elevance Health Inc. is a health benefits company. The company is headquartered in Indianapolis, Indiana.
Lam Research Corp
TECHNOLOGY · SEMICONDUCTOR EQUIPMENT & MATERIALS · USA
Lam Research Corporation is an American corporation that engages in the design, manufacture, marketing, and service of semiconductor processing equipment used in the fabrication of integrated circuits. Its products are used primarily in front-end wafer processing, which involves the steps that create the active components of semiconductor devices (transistors, capacitors) and their wiring (interconnects). The company also builds equipment for back-end wafer-level packaging (WLP), and for related manufacturing markets such as for microelectromechanical systems (MEMS). The company is headquartered in Fremont, California, in the Silicon Valley.
Compare with Other HEALTHCARE PLANS Stocks
Want to dig deeper into these stocks?